Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Lytix Biopharma AS is a biotechnology company specializing in the development of novel cancer immunotherapies. The primary function of Lytix Biopharma is to design and advance therapies that harness the body’s immune system to recognize and eradicate cancer cells. Its focus is on enhancing the effectiveness of cancer treatments through the development of oncolytic molecules that stimulate immune responses. Operating primarily in the biotechnology and healthcare sectors, Lytix Biopharma's innovative approach targets unmet medical needs, particularly in the treatment of tumors that may not respond well to conventional therapies. With its cutting-edge research and development processes, Lytix Biopharma plays a crucial role in the pharmaceutical landscape, offering potential new therapies that could improve outcomes for cancer patients globally. By pioneering solutions in immunotherapy, the company contributes to the broader goals of advancing personalized medicine and optimizing therapeutic results in oncology.
NOK 0.80
NOK 0.01 (-0.75%)
EOD Jul 1, 2026
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -NOK 60M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 0.00
▼ -100.0% YoY
Net Income (TTM)
-NOK 73M
▲ +36.4% YoY
Op. Margin
—
ROIC
-57.98%
▲ +35.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 76M
▲ +15.0% YoY
Op. Cash Flow (TTM)
-NOK 54M
▲ +39.7% YoY
Net Debt
-NOK 69M
Net Cash Position
Cash & Equiv.
NOK 72M
Continue Research
Lytix Biopharma AS (LYTIX.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Lytix Biopharma AS scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Lytix Biopharma AS scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -58.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh LYTIX.XOSL's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.